JP2022542886A5 - - Google Patents

Info

Publication number
JP2022542886A5
JP2022542886A5 JP2022504582A JP2022504582A JP2022542886A5 JP 2022542886 A5 JP2022542886 A5 JP 2022542886A5 JP 2022504582 A JP2022504582 A JP 2022504582A JP 2022504582 A JP2022504582 A JP 2022504582A JP 2022542886 A5 JP2022542886 A5 JP 2022542886A5
Authority
JP
Japan
Prior art keywords
polypeptide
optionally
tumor
masking agent
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022504582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542886A (ja
JP7682150B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/070308 external-priority patent/WO2021016640A1/en
Publication of JP2022542886A publication Critical patent/JP2022542886A/ja
Publication of JP2022542886A5 publication Critical patent/JP2022542886A5/ja
Application granted granted Critical
Publication of JP7682150B2 publication Critical patent/JP7682150B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022504582A 2019-07-25 2020-07-24 プロテアーゼ活性化治療剤を含む組成物および方法 Active JP7682150B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878574P 2019-07-25 2019-07-25
US62/878,574 2019-07-25
PCT/US2020/070308 WO2021016640A1 (en) 2019-07-25 2020-07-24 Compositions and methods comprising protease-activated therapeutic agents

Publications (3)

Publication Number Publication Date
JP2022542886A JP2022542886A (ja) 2022-10-07
JP2022542886A5 true JP2022542886A5 (cg-RX-API-DMAC7.html) 2023-08-02
JP7682150B2 JP7682150B2 (ja) 2025-05-23

Family

ID=74194303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022504582A Active JP7682150B2 (ja) 2019-07-25 2020-07-24 プロテアーゼ活性化治療剤を含む組成物および方法

Country Status (9)

Country Link
US (1) US20220281936A1 (cg-RX-API-DMAC7.html)
EP (1) EP4003401A4 (cg-RX-API-DMAC7.html)
JP (1) JP7682150B2 (cg-RX-API-DMAC7.html)
CN (1) CN114466657B (cg-RX-API-DMAC7.html)
AU (1) AU2020316002B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022001320A2 (cg-RX-API-DMAC7.html)
CA (1) CA3148621A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022000991A (cg-RX-API-DMAC7.html)
WO (1) WO2021016640A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
CN114206355A (zh) 2019-06-03 2022-03-18 芝加哥大学 用靶向癌症的佐剂治疗癌症的方法和组合物
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CN115943210A (zh) 2020-01-20 2023-04-07 中外制药株式会社 配体结合融合蛋白
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
KR20230157448A (ko) 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
US20240228586A1 (en) * 2021-05-07 2024-07-11 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
KR20240035556A (ko) 2021-07-19 2024-03-15 추가이 세이야쿠 가부시키가이샤 융합 폴리펩타이드를 이용하는 프로테아제 매개성의 표적 특이적 사이토카인 송달
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
US20240390506A1 (en) * 2021-09-28 2024-11-28 Suzhou Fuse Biosciences Limited Immunoconjugates containing tnf-alpha and related methods and compositions thereof
KR102609822B1 (ko) * 2021-10-05 2023-12-06 (주)케어젠 항염증 활성을 갖는 펩타이드와 이의 용도
IL312221A (en) 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof
CN113995855A (zh) * 2021-11-10 2022-02-01 中国药科大学 一种抗纤维化纳米载体和纳米制剂及其制备方法
CN114272390B (zh) * 2021-12-29 2022-09-02 中山大学附属第一医院 一种微环境靶向联合细胞靶向肿瘤抑制载体及其制备方法和应用
JP2025538387A (ja) 2022-11-16 2025-11-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド プロテアーゼ切断可能なリンカーを有する膜結合il-12を含むキメラタンパク質
CN119060196A (zh) * 2023-05-31 2024-12-03 郑州大学 一种金属蛋白酶激活型car-t结构的制备及其应用
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0638644A1 (en) * 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
US6387663B1 (en) * 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
WO2007001677A2 (en) * 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
WO2007112051A2 (en) * 2006-03-24 2007-10-04 The Board Of Trustees Of The University Of Illinois Polypyrimidine-tract binding protein (ptb) as a biomarker and target for the diagnosis and treatment of cancer
US8734774B2 (en) * 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
WO2016023040A1 (en) * 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
IL300408B2 (en) * 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
CA3018145C (en) * 2016-03-18 2024-09-17 Persevere Therapeutics Inc. TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER
US10906957B2 (en) * 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
WO2018184003A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
EP3634465A4 (en) * 2017-05-25 2021-01-20 The Broad Institute, Inc. LYMPHOCYTE ANTIGEN CD5 SIMILAR (CD5L) MONOMER, HOMODIMER AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHOD OF USE THEREOF
JP2020528878A (ja) * 2017-06-20 2020-10-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム がん治療用インターフェロンプロドラッグ
CN110396133B (zh) * 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020041758A1 (en) * 2018-08-24 2020-02-27 City Of Hope Masked cytokine conjugates
US20240228586A1 (en) * 2021-05-07 2024-07-11 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents

Similar Documents

Publication Publication Date Title
JP2024517871A5 (cg-RX-API-DMAC7.html)
CN113226472A (zh) 双免疫细胞衔接物
US20200048331A1 (en) Immunoregulatory structures from normally occuring proteins
JP7848182B2 (ja) 改善された抗原結合受容体
CA2289912A1 (en) Human receptor proteins; related reagents and methods
US20080299137A1 (en) Fusion Proteins That Bind Effector Lymphocytes And Target Cells
US11352413B2 (en) Engineered PD-1 variants
CA2561826A1 (en) Linear single chain recombinant anti-cea/cd3/cd28 trispecific antibody
CA2386463A1 (en) April receptor (bcma) and uses thereof
WO2021092075A1 (en) IL-2RβγC BINDING COMPOUNDS
CN105744944B (zh) 免疫系统调节器
JP2022542886A (ja) プロテアーゼ活性化治療剤を含む組成物および方法
JP2016525551A5 (cg-RX-API-DMAC7.html)
ATE468127T1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
JP2023547447A (ja) 改良型抗原結合受容体
Avery et al. Characterization of factor H binding to human polymorphonuclear leukocytes.
Milne et al. Monoclonal antibodies against human low density lipoprotein: stoichiometric binding studies using Fab fragments
KR20220093323A (ko) HLA-A2/WT1 x CD3 이중특이적 항체 및 레날리도미드를 이용한 암의 치료
KR20240111753A (ko) 개선된 항원 결합 수용체
JP2025121986A5 (cg-RX-API-DMAC7.html)
JP2022535816A5 (cg-RX-API-DMAC7.html)
CN119278052A (zh) 预防或减轻与t细胞接合剂相关的不良反应
US20260103528A1 (en) Nanobodies that bind to gprc5d and uses thereof
JP2026048706A5 (cg-RX-API-DMAC7.html)
KR101974583B1 (ko) 링커 폴리펩티드 및 이를 이용한 표적 물질 분석 방법